Ivosidenib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 250 mg
Reference Brands: Tibsovo (USA/EU)
Category:
Oncology Cancer Care
Ivosidenib is available in Tablets
and strengths such as 250 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ivosidenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ivosidenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ivosidenib is a targeted anticancer therapy used alone or in combination with other treatments for adults with specific cancers that carry a mutation in the IDH1 gene. It is primarily indicated for the treatment of acute myeloid leukemia, cholangiocarcinoma (bile duct cancer), and certain types of myelodysplastic syndromes with confirmed IDH1 mutations. Genetic testing is required before treatment to ensure appropriate patient selection.
Ivosidenib works by selectively inhibiting the abnormal protein produced by the mutated IDH1 gene. By blocking this enzyme, the drug helps restore normal cellular differentiation and limits the uncontrolled growth of cancer cells. This targeted mechanism allows for a more precise treatment approach compared to conventional chemotherapy.
In addition to its approved indications, ivosidenib is being studied in clinical trials for the treatment of other IDH1-mutated cancers. It belongs to the class of enzyme inhibitors and is categorized as a targeted therapy. Ivosidenib is marketed under the brand name Tibsovo and is administered orally under specialist supervision, with regular monitoring required during treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing